|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide. IARC CancerBase. No. 11. 20162016.
|
|
2
|
Campana JP and Meyers AD: The surgical
management of oral cancer. Otolaryngol Clin North Am. 39:331–348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen L, Gajendrareddy PK and DiPietro LA:
Differential expression of HIF-1α in skin and mucosal wounds. J
Dent Res. 91:871–876. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janssen HL, Haustermans KM, Balm AJ and
Begg AC: Hypoxia in head and neck cancer: How much, how important?
Head Neck. 27:622–638. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toustrup K, Sørensen BS, Alsner J and
Overgaard J: Hypoxia gene expression signatures as prognostic and
predictive markers in head and neck radiotherapy. Semin Radiat
Oncol. 22:119–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olive PL, Banáth JP and quino-Parsons C:
Measuring hypoxia in solid tumours-is there a gold standard? Acta
Oncol. 40:917–923. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Le QT: Identifying and targeting hypoxia
in head and neck cancer: A brief overview of current approaches.
Int J Radiat Oncol Biol Phys. 69 (2 Suppl):S56–S58. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oliveira LR and Ribeiro-Silva A:
Prognostic significance of immunohistochemical biomarkers in oral
squamous cell carcinoma. Int J Oral Maxillofac Surg. 40:298–307.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaluz S, Kaluzova M, Liao SY, Lerman M and
Stanbridge EJ: Transcriptional control of the tumor- and
hypoxia-marker carbonic anhydrase 9: A one transcription factor
(HIF-1) show? Biochim Biophys Acta. 1795:162–172. 2009.PubMed/NCBI
|
|
11
|
Hoogsteen IJ, Marres HA, Bussink J, van
der Kogel AJ and Kaanders JH: Tumor microenvironment in head and
neck squamous cell carcinomas: Predictive value and clinical
relevance of hypoxic markers. Head Neck. 29:591–604. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McDonald PC, Winum JY, Supuran CT and
Dedhar S: Recent developments in targeting carbonic anhydrase IX
for cancer therapeutics. Oncotarget. 3:84–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brockton N, Dort J, Lau H, Hao D, Brar S,
Klimowicz A, Petrillo S, Diaz R, Doll C and Magliocco A: High
stromal carbonic anhydrase IX expression is associated with
decreased survival in P16-negative head-and-neck tumors. Int J
Radiat Oncol Biol Phys. 80:249–257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brockton NT, Klimowicz AC, Bose P,
Petrillo SK, Konno M, Rudmik L, Dean M, Nakoneshny SC, Matthews TW,
Chandarana S, et al: High stromal carbonic anhydrase IX expression
is associated with nodal metastasis and decreased survival in
patients with surgically-treated oral cavity squamous cell
carcinoma. Oral Oncol. 48:615–622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sowter HM, Raval RR, Moore JW, Ratcliffe
PJ and Harris AL: Predominant role of hypoxia-inducible
transcription factor (Hif)-1alpha versus Hif-2alpha in regulation
of the transcriptional response to hypoxia. Cancer Res.
63:6130–6134. 2003.PubMed/NCBI
|
|
16
|
BelAiba RS, Bonello S, Zähringer C,
Schmidt S, Hess J, Kietzmann T and Görlach A: Hypoxia up-regulates
hypoxia-inducible factor-1alpha transcription by involving
phosphatidylinositol 3-kinase and nuclear factor kappaB in
pulmonary artery smooth muscle cells. Mol Biol Cell. 18:4691–4697.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pore N, Jiang ZB, Shu HK, Bernhard E, Kao
GD and Maity A: Akt1 activation can augment hypoxia-inducible
factor-1alpha expression by increasing protein translation through
a mammalian target of rapamycin-independent pathway. Mol Cancer
Res. 4:471–479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaluz S, Kaluzova M, Chrastina A, Olive
PL, Pastoreková S, Pastorek J, Lerman MI and Stanbridge EJ: Lowered
oxygen tension induces expression of the hypoxia marker MN/carbonic
anhydrase IX in the absence of hypoxia-inducible factor 1 alpha
stabilization: A role for phosphatidylinositol 3′-kinase. Cancer
Res. 62:4469–4477. 2002.PubMed/NCBI
|
|
21
|
Sullivan R and Graham CH: Hypoxia-driven
selection of the metastatic phenotype. Cancer Metastasis Rev.
26:319–331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jubb AM, Buffa FM and Harris AL:
Assessment of tumour hypoxia for prediction of response to therapy
and cancer prognosis. J Cell Mol Med. 14:18–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klimowicz AC, Bose P, Petrillo SK,
Magliocco AM, Dort JC and Brockton NT: The prognostic impact of a
combined carbonic anhydrase IX and Ki67 signature in oral squamous
cell carcinoma. Br J Cancer. 109:1859–1866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pastorekova S, Ratcliffe PJ and Pastorek
J: Molecular mechanisms of carbonic anhydrase IX-mediated pH
regulation under hypoxia. BJU Int. 101 Suppl 4:S8–S15. 2008.
View Article : Google Scholar
|
|
25
|
Søland TM and Brusevold IJ: Prognostic
molecular markers in cancer-quo vadis? Histopathology. 63:297–308.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen C, Méndez E, Houck J, Fan W,
Lohavanichbutr P, Doody D, Yueh B, Futran ND, Upton M, Farwell DG,
et al: Gene expression profiling identifies genes predictive of
oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev.
17:2152–2162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC
Working Group on Cancer Diagnostics: Reporting recommendations for
tumor marker prognostic studies. J Clin Oncol. 23:9067–9072. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klimowicz AC, Bose P, Nakoneshny SC, Dean
M, Huang L, Chandarana S, Magliocco AM, Matthews Wayne T, Brockton
NT and Dort JC: Basal Ki67 expression measured by digital image
analysis is optimal for prognostication in oral squamous cell
carcinoma. Eur J Cancer. 48:2166–2174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bose P, Klimowicz AC, Kornaga E, Petrillo
SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT and Dort
JC: Bax expression measured by AQUAnalysis is an independent
prognostic marker in oral squamous cell carcinoma. BMC Cancer.
12:3322012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gustavson MD, Bourke-Martin B, Reilly DM,
Cregger M, Williams C, Tedeschi G, Pinard R and Christiansen J:
Development of an unsupervised pixel-based clustering algorithm for
compartmentalization of immunohistochemical expression using
automated QUantitative Analysis. Appl Immunohistochem Mol Morphol.
17:329–337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ljungkvist AS, Bussink J, Rijken PF,
Kaanders JH, van der Kogel AJ and Denekamp J: Vascular
architecture, hypoxia, and proliferation in first generation
xenografts of human head-and-neck squamous cell carcinomas. Int J
Radiat Oncol Biol Phys. 54:215–228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hoogsteen IJ, Marres HA, Wijffels KI,
Rijken PF, Peters JP, van den Hoogen FJ, Oosterwijk E, van der
Kogel AJ and Kaanders JH: Colocalization of carbonic anhydrase 9
expression and cell proliferation in human head and neck squamous
cell carcinoma. Clin Cancer Res. 11:97–106. 2005.PubMed/NCBI
|
|
35
|
Kondo Y, Yoshikawa K, Omura Y, Shinohara
A, Kazaoka Y, Sano J, Mizuno Y, Yokoi T and Yamada S:
Clinicopathological significance of carbonic anhydrase 9, glucose
transporter-1, Ki-67 and p53 expression in oral squamous cell
carcinoma. Oncol Rep. 25:1227–1233. 2011.PubMed/NCBI
|
|
36
|
Sparano A, Quesnelle KM, Kumar MS, Wang Y,
Sylvester AJ, Feldman M, Sewell DA, Weinstein GS and Brose MS:
Genome-wide profiling of oral squamous cell carcinoma by
array-based comparative genomic hybridization. Laryngoscope.
116:735–741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wykoff CC, Beasley NJ, Watson PH, Turner
KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell
PH, et al: Hypoxia-inducible expression of tumor-associated
carbonic anhydrases. Cancer Res. 60:7075–7083. 2000.PubMed/NCBI
|
|
38
|
Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil
L, Johnson BE, Stanbridge EJ and Lerman MI: Down-regulation of
transmembrane carbonic anhydrases in renal cell carcinoma cell
lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci
USA. 95:12596–12601. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chrastina A: High cell density-mediated
pericellular hypoxia is a crucial factor inducing expression of the
intrinsic hypoxia marker CA IX in vitro in HeLa cells. Neoplasma.
50:251–256. 2003.PubMed/NCBI
|
|
40
|
Ross JS, Hatzis C, Symmans WF, Pusztai L
and Hortobágyi GN: Commercialized multigene predictors of clinical
outcome for breast cancer. Oncologist. 13:477–493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nielsen TO, Parker JS, Leung S, Voduc D,
Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, et
al: A comparison of PAM50 intrinsic subtyping with
immunohistochemistry and clinical prognostic factors in
tamoxifen-treated estrogen receptor-positive breast cancer. Clin
Cancer Res. 16:5222–5232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cronin M, Sangli C, Liu ML, Pho M, Dutta
D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical
validation of the oncotype DX genomic diagnostic test for
recurrence prognosis and therapeutic response prediction in
node-negative, estrogen receptor-positive breast cancer. Clin Chem.
53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bartlett JM, Bayani J, Marshall A, Dunn
JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron
DA, et al: Comparing breast cancer multiparameter tests in the
OPTIMA prelim trial: No test is more equal than the others. J Natl
Cancer Inst. 108:pii: djw050. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chi JT, Wang Z, Nuyten DS, Rodriguez EH,
Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A,
Børresen-Dale AL, et al: Gene expression programs in response to
hypoxia: Cell type specificity and prognostic significance in human
cancers. PLoS Med. 3:e472006. View Article : Google Scholar : PubMed/NCBI
|
